Form 4 for MRNA Moderna
Accepted 2022-03-21 00:00:00 ET · period of report 2022-03-17 · accession 0001127602-22-010098 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-21 | 2022-03-17 | MRNA | Hoge Stephen | Pres | M - OptEx | $151.33 | +19.3K | 1.63M | +1% | +$2.92M |
| D | 2022-03-21 | 2022-03-18 | MRNA | Hoge Stephen | Pres | S - Sale+OE | $171.67 | -7,541 | 1.62M | -0.5% | -$1.29M |
| D | 2022-03-21 | 2022-03-17 | MRNA | Hoge Stephen | Pres | M - OptEx | $0.00 | -19.3K | 19.3K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-17 | M | A | 19,282 | $151.33 | 1,630,073 | D | — | — | (F1) Reflects the date of delivery of RSUs that were scheduled for vesting on February 28, 2022, but for which delivery was delayed until certain antitrust clearance requirements were obtained. |
| 2 | Common | Common Stock | 2022-03-18 | S | D | 7,541 | $171.67 | 1,622,532 | D | — | — | |
| 3 | Derivative | Restricted Stock Units | 2022-03-17 | M | D | 19,282 | $0.00 | 19,283 | D | $0.00 · 2022-02-28 to — | 19,282 Common Stock | (F1) Reflects the date of delivery of RSUs that were scheduled for vesting on February 28, 2022, but for which delivery was delayed until certain antitrust clearance requirements were obtained. (F5) 50% of the shares subject to this restricted stock unit award vested on February 28, 2022 with the remainder vesting in eight (8) equal quarterly installments thereafter. |